Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRXBiotechnology
Healthcare
$6.21 +1.11%
+$0.07 today
- Market cap
- $417.57M
- Beta
- 1.48
- P/E (TTM)
- -8.5
- EPS (TTM)
- -$0.74
52W Low $4.19High $9.32
Volume 1.21M
Average 0.22M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$53.66M
FY 2025 · Annual
Net Income
-$53.86M
FY 2025 · Annual
Income Statement
Mixed currencies
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 112.38K | 0 | 0 | 163.47K | 331.89K |
| Gross Profit | (112.38K) | 0 | 0 | (163.47K) | (331.89K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 7.59M | 13.63M | 15.33M | 16.07M | 29.51M |
| Selling, General & Admin | 6.97M | 3.99M | 5.63M | 10.92M | 17.1M |
| Operating Expenses | 14.65M | 17.62M | 20.97M | 26.99M | 53.33M |
| Depreciation & Amortization | 87.47K | 147.89K | 117.1K | 171.6K | 331.89K |
| EBITDA | (17.22M) | (17.86M) | (20.78M) | (24.95M) | (53.33M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (14.65M) | (17.62M) | (20.97M) | (26.99M) | (53.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 51.55K | 431.8K | 649.75K | 1.16M | 1.41M |
| Interest Expense | 1.02M | 982.86K | 881.05K | 603.17K | 0 |
| Other Income / Expenses | (3.68M) | (1.37M) | (814.93K) | 1.26M | (212.94K) |
| Income Before Tax | (18.33M) | (18.99M) | (21.78M) | (25.73M) | (53.87M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 27.42K | 1.8K | 26.65K |
| Net Income | (18.03M) | (18.49M) | (21.25M) | (25.49M) | (53.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.63) | (0.96) | (0.88) | (0.76) | (1.05) |
| EPS (Diluted) | (1.63) | (0.96) | (0.88) | (0.76) | (1.05) |
| 14.24M | 19.29M | 24.15M | 33.93M | 39.96M | |
| 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
EPRX Earnings Waterfall · TTM
NASDAQ:EPRX · Revenue to Net Income
Key Ratios
EPS$-1.00
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-7.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$42.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.00, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-8 | S-8 filing | Nov 12, 2026 | |
| 6-K | 6-K filing | Nov 10, 2026 | |
| 6-K | 6-K filing | Nov 10, 2026 | |
| 6-K | 6-K filing | Nov 10, 2026 | |
| 6-K | 6-K filing | Nov 10, 2026 |
How much revenue does EPRX generate?
Eupraxia Pharmaceuticals Inc. (EPRX) reported $0.00 of revenue in fiscal 2025.
Is EPRX profitable?
Eupraxia Pharmaceuticals Inc. (EPRX) reported -$53.86M of net income.
Continue the stock analysis
Jump to another research area for this company.